ERBB2 and neoplasm: The diagnostic criteria of the HERACLES study defined HER2 positivity as 3+ (expression in less than 50% of cells), 2+ (moderate positivity with expression in less than 50% of cells), or 3+ expression in more than 10% but less than 50% of tumor cells.